Active, not recruitingPhase 2NCT05144841
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Zilovertamab vedotin(biological)
- Enrollment
- 140 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0229), Orange, California, United States
- Innovative Clinical Research Institute ( Site 0202), Whittier, California, United States
- Georgetown University Medical Center ( Site 0204), Washington D.C., District of Columbia, United States
- Northside Hospital ( Site 0206), Atlanta, Georgia, United States
- University of Chicago Medical Center ( Site 0207), Chicago, Illinois, United States
- Franciscan St. Francis Health ( Site 0225), Indianapolis, Indiana, United States
- University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 0211), Baltimore, Maryland, United States
- Massachusetts General Hospital-Cancer Center Protocol Office ( Site 0203), Boston, Massachusetts, United States
- University of Michigan ( Site 0200), Ann Arbor, Michigan, United States
- Karmanos Cancer Institute ( Site 0216), Detroit, Michigan, United States
- Saint Louis University Cancer Center ( Site 0209), St Louis, Missouri, United States
- Atlantic Health System Morristown Medical Center ( Site 0213), Morristown, New Jersey, United States
- New York Medical College ( Site 0215), Valhalla, New York, United States
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0217), Cincinnati, Ohio, United States
- University Hospitals Cleveland Medical Center ( Site 0222), Cleveland, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05144841 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.